BioProcess International editor in chief Anne Montgomery interviewed Thomas C. Ransohoff, vice president and principal consultant, BioProcess Technology Consultants, at the BPI Conference and Exposition in Boston, MA, in October 2015. Sponsored by Click here to view the other videos in this series.
BioProcess International editor in chief Anne Montgomery spoke with Pete Gagnon, Group Manager, Downstream Processing, Bioprocessing Technology Institute, Singapore, at the BioProcess International Conference and Exposition in Boston, MA, October 2015. Sponsored by Click here to view the other videos in this series.
BioProcess International editor in chief, Anne Montgomery, interviewed Giorgio Carta, Lawrence R. Quarles Professor, Department of Chemical Engineering, University of Virginia at the BioProcess International Conference and Exposition in Boston, MA, in October 2015. Sponsored by Click here to view the other videos in this series.
The antibody therapeutics market is enjoying high growth rates, the major areas of therapeutic application being cancer and immune/inflammation-related disorders including arthritis and multiple sclerosis. In 2013, six of the top ten best-selling global drug brands were monoclonal antibodies (mAbs) and more than 400 mAbs were in clinical trials. The characterization of these complex biomolecules is a major challenge in process monitoring and quality control. The main product characteristics to be monitored are aggregate and fragment content, glycosylation pattern and…
BioProcess International editor in chief Anne Montgomery spoke with Dr. Carsten Voß, application specialist, Process Chromatography, Bio-Rad Laboratories GmbH at the BioProcess International Conference and Exposition in Boston, MA, October 2015. Sponsored by Click here to view the other videos in this series.
The development and manufacture of biotherapeutics requires efficient and timely analytical support to monitor both quantity and quality in products and processes. Productivity is important already during early development. Further downstream, selected cell lines must be optimized for productivity, followed by bioprocess development to yield g/L concentrations of IgG product. The immunoassays that are often used to determine IgG titer must have the flexibility to measure the broad range of concentrations encountered during cell-line and process development, and Gyrolab huIgG…
This webcast features: Dominic Clarke, Global Product Manager, Charter Medical Working cell banks (WCB’s) are commonly applied to initiate cell culture manufacturing campaigns for production of recombinant or therapeutic proteins. These campaigns typically begin with inoculation of cells previously cryopreserved in cryovials. While cryovials are typically used in the development of WCB’s and initiation of manufacturing campaigns, they are not optimal for the growing demands of commercial production. Cryovials are small and filling/removal is performed through an open screw cap. This…
Faron Pharmaceuticals Oy (â€Faronâ€), the clinical stage biopharmaceutical company, announced today it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platformâ„¢ and SURE CHO-M Cell Lineâ„¢ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody. Selexis SUREtechnology will enable the rapid generation of high expressing clonal cells for the production of monoclonal antibodies.…
Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, today introduced the new ambr® 15 fermentation system, an automated micro bioreactor system designed to enhance microbial strain screening with advanced capabilities supporting fed-batch microbial cultures. The new system, based on the gold-standard ambr 15 micro bioreactor technology, has been designed to meet the requirements of microbial fermentation. It comprises 24 single-use stirred micro bioreactors (each with an 8-12 mL working volume) integrated to a user-friendly, automated workstation.…
This webcast features: Gareth Meek-Brown, Lead Scientist, Lonza Biologics – Slough Product Quality assessment during Upstream and Downstream Process Development is key to the production of safe and efficacious biopharmaceuticals. Critical quality attributes such as N-linked glycosylation are highly dependent upon biosynthesis conditions and play a crucial role in the pharmacology of therapeutic proteins, potentially affecting immunogenicity, pharmacokinetics and pharmacodynamics. The presence of N-linked glycosylation has benefits including increased thermal, physical and chemical stability over aglycosylated variants. The optimum N-linked…